



(FORMERLY GENOVATION CAPITAL CORP.)

MANAGEMENT'S DISCUSSION & ANALYSIS

For the Year Ended November 30, 2016

The following management's discussion and analysis ("MD&A") of the financial condition and results of the operations of Valens GroWorks Corp. ("VGW" or the "Company") constitutes management's review of the factors that affected the Company's financial and operating performance for the year ended November 30, 2016. This MD&A has been prepared in compliance with the requirements of National Instrument 51-102 - Continuous Disclosure Obligations. This discussion should be read in conjunction with the audited annual consolidated financial statements of the Company for the years ended November 30, 2015 and 2016, together with the notes thereto. Results are reported in Canadian dollars, unless otherwise noted. In the opinion of management, all adjustments (which consist only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results for the year ended November 30, 2016 are not necessarily indicative of the results that may be expected for any future period. Information contained herein is presented as at March 29, 2017 unless otherwise indicated.

On November 2, 2016, the Company completed the acquisition (the "Acquisition") of Valens Agritech Ltd. ("VAL") pursuant to a share exchange agreement dated October 31, 2016 (the "Agreement"). The Acquisition constituted a reverse takeover ("RTO"). Upon completion of the Acquisition, the Company changed its name from Genovation Capital Corp. to Valens GroWorks Corp. The financial information is that of VAL and replaces amounts previously reported by the Company.

For the purposes of preparing this MD&A, management, in conjunction with the Board of Directors, considers the materiality of information. Information is considered material if: (i) such information results in, or would reasonably be expected to result in, a significant change in the market price or value of VGW common shares; or (ii) there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision; or (iii) it would significantly alter the total mix of information available to investors. Management, in conjunction with the Board of Directors, evaluates materiality with reference to all relevant circumstances, including potential market sensitivity.

All financial information contained in this MD&A is current as of March 29, 2017 unless otherwise stated.

All financial information in this MD&A has been prepared in accordance with International Financial Reporting Standards ("IFRS") and all dollar amounts are expressed in Canadian dollars, unless otherwise specified.

Additional information regarding the Company is available on SEDAR at www.sedar.com, and the Company's website www.valensgroworks.ca. The date of this MD&A is March 29, 2017.

FORWARD-LOOKING INFORMATION

Inherent in forward-looking statements involve known and unknown risks, and factors may include, but are not limited to: unavailability of financing, changes in government regulation, general economic condition, general business conditions, limited time being devoted to business by directors, escalating professional fees, escalating transaction costs, competition, fluctuation in foreign exchange rates, competition, stock market volatility, unanticipated operating events and liabilities inherent in industry. Readers are cautioned that the foregoing list of important factors and assumptions is not exhaustive. Forward-looking statements are not guarantees of future performance. Events or circumstances could cause the Company's actual results to differ materially from those estimated or projected and expressed in, or implied by, these forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, whether as a result of new information or future events or otherwise, except as may be required under applicable laws.

Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this MD&A. Such statements are based on a number of assumptions which may

prove to be incorrect, including, but not limited to, the following assumptions: that there is no material deterioration in general business and economic conditions; that there is no unanticipated fluctuation of interest rates and foreign exchange rates; that the supply and demand for, deliveries of, and the level and volatility of commodity prices develop as expected; that the Company receives regulatory and governmental approvals as are necessary on a timely basis; that the Company is able to obtain financing as necessary on reasonable terms; that there is no unforeseen deterioration in the Company's activity costs; that the Company is able to continue to secure adequate transportation as necessary for its exploration activities; that the Company is able to procure equipment and supplies, as necessary, in sufficient quantities and on a timely basis; that exploration activity timetables and capital costs for the Company's planned projects are not incorrectly estimated or affected by unforeseen circumstances; that costs of closure of various operations are accurately estimated; that there are no unanticipated changes to market competition; that the Company's estimates in relation to its natural resource interests are within reasonable bounds of accuracy and that the geological, operational and price assumptions on which these are based are reasonable; that no environmental and other proceedings or disputes arise; and that the Company maintains its ongoing relations with its employees, consultants and advisors.

Readers are cautioned that the foregoing list of important factors and assumptions is not exhaustive. Forward-looking statements are not guarantees of future performance. Events or circumstances could cause the Company's actual results to differ materially from those estimated or projected and expressed in, or implied by, these forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, whether as a result of new information or future events or otherwise, except as may be required under applicable laws.

The forward-looking statements contained herein are based on information available as of March 29, 2017.

DESCRIPTION OF BUSINESS & OUTLOOK

The Company was incorporated under the laws of British Columbia on January 14, 1981. The Company's common shares trade under the trading symbol "VGW" on the Canadian Securities Exchange ("CSE"). VAL was incorporated under the Business Corporations Act of the Province of British Columbia on April 14, 2014.

The Company operates in one business segment being the scientific research of phytopharmaceutical material, specifically producing cannabis and cannabis related products.

REVERSE TAKE OVER

On November 2, 2016, the Company completed the Acquisition of VAL. To complete the Acquisition, the following occurred:

- The Company acquired all the issued and outstanding shares of VAL in exchange for 36,000,000 common shares of the Company.
- Outstanding stock options and warrants of the Company were re-issued at the date of the Acquisition under the same terms of the originally granted stock options and warrants.
- The Company entered into a referral agreement with Greg Patchell and Tyler Robson, whereby the Company paid total finders' fee of 675,000 common shares on closing of the Acquisition. The fair value of the 675,000 common shares was determined to be \$337,500 using the minimum share price of the required financing as described below.

As part of the Acquisition the Company is required to complete one of more financings within three months after the Acquisition date to raise net proceeds of not less than \$1,200,000. The financing must be completed at a minimum price per share of \$0.50.

As a result of the Acquisition, VAL controlled the Company and is considered to have acquired the Company. The Company did not meet the definition of a business and the Acquisition was accounted for as the purchase of the Company's net assets by VAL. The net purchase price was determined as equity settled share-based payment, under IFRS 2, Share-based payment, at the fair value of the equity instruments of the Company retained by the shareholders of the Company, based on the market value of the Company's common shares.

The Acquisition costs related to the RTO plus the aggregate of the fair value of the consideration paid less the net assets acquired has been recognized as a listing expense in the statement of loss and comprehensive loss. These consolidated

financial statements reflect the assets, liabilities and operation of VAL since its incorporation and of the Company from November 2, 2016.

The fair value of net assets (liabilities) of the Company as at the date of the Acquisition was:

| | |
|--|------------|
| Cash | \$ 8,912 |
| Receivables | 88,766 |
| Promissory note receivable, MKHS LLC | 1,083,700 |
| Accounts payable and accrued liabilities | (738,724) |
| Net monetary assets acquired | \$ 442,654 |

The consideration consists of 14,347,668 commons shares valued at \$7,173,835, 675,000 common shares issued under the referral agreement valued at \$337,500 and 405,000 replacement stock options issued.

The fair value of \$174,584 was assigned to the 405,000 stock options as estimated by using the Black-Scholes valuation model with the following weighted average assumptions: expected dividend yield of 0%, expected volatility of 200%, risk free rate of return of 0.54% and an expected maturity of 3.31 years.

| | |
|------------------------------|--------------|
| Common shares issued | \$ 7,511,335 |
| Replacement options | 174,584 |
| Net monetary assets acquired | \$ 7,685,919 |

| | |
|-----------------|--------------|
| Listing expense | \$ 7,243,265 |
|-----------------|--------------|

SIGNIFICANT EVENTS, TRANSACTIONS AND ACTIVITIES

On November 2, 2015 the Company announced entering into an arm's length non-binding letter of intent with MKHS, LLC ("MKHS") which outlines the general terms and conditions of a proposed transaction pursuant to which the Company proposes to acquire all of the issued and outstanding securities of MKHS in exchange for common shares of the Company (the "MKHS Transaction"). On November 24, 2015 the Company announced entering into a binding commitment letter with MKHS in respect of the MKHS Transaction.

During the year ended November 30, 2016 the Company and MKHS decided not to complete the share exchange transaction and on January 16, 2017 the Company entered into a 5-year, renewable, Professional Services Agreement (the "PSA") with MKHS Ventures. As a result of the Arrangement, MKHS Ventures will complete the buildout of a 28,000-sf Farmtek greenhouse expansion as proposed and funded by the Company under the original agreements (the "Buildout"). In accordance with the PSA, payments of US\$60,000 per month for management services will commence to the Company upon completion of the Buildout, with the three initial monthly payments to be deferred and paid at the end of third month following the Buildout to allow for an initial harvest. In addition, the Company will provide consulting services to be performed and invoiced monthly, and will be reimbursed for approved out-of-pocket expenses and sub-contracted services. The Buildout is currently under construction and is expected to be completed within the next year.

On January 16, 2017 the Company also entered into the loan agreement with MKV Ventures which is secured by a promissory note for the total loan amount of \$1,628,266 (US\$1,212,500). The loan is guaranteed by MKHS and secures repayment of previous advances made by the Company. The loan accrues interest at the rate of 15% per annum effective May 15, 2016. Principal and interest, as well as \$30,000 in cost recoveries for past accrued fees, are payable to the Company by MKHS in arrears commencing at the end of the third month following Buildout, and on the 15th day of each month thereafter over a 5-year term.

The agreements entered into on January 16, 2017, supersede and replaces all previous agreements entered into between the Company and MKHS and settles all outstanding issues between the parties.

On November 2, 2016 the Company completed the acquisition of all the issued and outstanding shares of VAL as described above. Effective on the closing of the Acquisition, Chris Cooper, Leslie van Santen and Michael Wystrach resigned as directors of the Company and were replaced by VAL appointees Dave Gervais and Tim Tombe. Existing Company directors John Binder, Tyler Robson and Robert van Santen remain on the reconstituted five-member Board.

The Company appointed Gordon J. Fretwell, outside legal counsel, as corporate secretary. Robert van Santen remains as Chief Executive Officer and Chairman of the Board, with Annie Storey as Chief Financial Officer. The directors, officers and key employees of VAL, the Company's wholly-owned subsidiary, consists of David Gervais, President and Director, Tim Tombe, Corporate Secretary and Director, Tyler Robson, Director of Operations, and Yasantha Athukorala, Chief Scientific Officer.

Effective November 24, 2016 the Company completed its corporate name change to Valens GroWorks Corp. The Canadian Securities Exchange listing of the Company's common shares is trading under the new name and trading symbol "VGW" following the issue of the CSE's bulletin to dealers. The Company's new CUSIP number will be 91913D106 and the new ISIN will be CA91913D1069. There is no change to the Company's share structure.

On December 20, 2016 and January 11, 2017 the Company closed a two tranche non-brokered private placement of 2,153,190 units (the "Unit") at a price of \$0.65 per Unit for gross proceeds of \$683,074 and repayment of debt of \$716,500 (the "Offering"). Each Unit consisted of one common share of the Company and one-half of a common share purchase warrant. Each warrant will entitle the holder thereof to purchase one common share at a price of \$1.15 for a period of 12 months from the closing of the Offering. The Company will be entitled to accelerate the expiry date of the warrants to the date that is 30 days following the date the Company issues a news release announcing that the closing price of the common shares on the CSE has been equal to or greater than \$1.65 for ten consecutive trading days after the statutory hold period to the expiry date. The net proceeds from the Offering will be used by the Company for security upgrades to the Company's R&D facility in Kelowna and general corporate purposes, including the partial repayment of related party loans and accrued payables.

On January 13, 2017 the Company announced the completion, by the Regional Inspectorate of the Office of Controlled Substances of Health Canada, of their final inspection of VAL's 17,000 square foot R&D facility located in Kelowna, British Columbia. The inspection is the final stage required to achieve licensing under our application for a Controlled Drugs and Substances Dealer's License to enable the cultivation and processing of marijuana (such as creating extracts or derivatives) for the purpose of research, for processing manufacturing derivatives, and for transporting product to other locations (including related packaging, possession, sale, delivery and research activities). Final pre-inspection preparation included the installation of significant enhanced physical security measures, the establishment of specified record keeping procedures, and the engagement of a Qualified Person In Charge (QPIC).

On February 9, 2017 the Company issued a convertible unsecured note (the "Note") to a non-arm's length lender, a company controlled by a director of the Company (the "Lender"), for an aggregate principal amount of \$500,000. THE CEO of the Company has personally guaranteed the prompt, punctual and full repayment of the Note when due. The Lender has the option but not an obligation to exchange all or part of the Note and accrued interest (the "Option Exercise") into common shares of the Company under the same terms and conditions as in the Offering. The Note will mature in one year and bear interest at 10% per annum from the date the funds were advanced until the earlier of:

- the date the Note, together with all accrued interest, is repaid in full; and
- the date of completion of the Option Exercise.

Note proceeds will be used for the purposes of meeting Company acquisition and expansion obligations and for general corporate purposes.

On February 10, 2017 the Company announced the appointment of Tyler Robson, currently a director of the Company, as its Chief Operating Officer. Mr. Robson also continues as Director of Operations of VAL, the Company's wholly-owned operating subsidiary in Kelowna, B.C.

On February 27, 2017 the Company entered into a definitive share purchase agreement (the "Share Purchase Agreement") with DHomeNest Holdings Inc. and four minority employee-shareholders to acquire Supra THC Services Inc. ("Supra"). The Share Purchase Agreement provides that the Company will acquire 100% of the issued and outstanding shares of Supra for \$3.75 million, to be fully satisfied through the issuance of three million shares of the Company. The total share consideration is subject to a regulatory four month hold period as well as a 36-month escrow agreement. Supra's Dealer's License allows for the possession of cannabis and related active ingredients as well as the production of extracts for the purpose of analysis.

Expected revenue-generating activities include leading edge scientific research and development of products and services related to the medical cannabis industry, the supply of a superior line of products with a measurable standard of excellence, as well as toll processing for licensed producers, including the use of a proprietary process that generates 100% Cannabis oil without the addition of any solvents.

The Company also announced the appointment of Dr. Rob O'Brien as President and Chief Science Officer (CSO) of VAL. Dr. O'Brien is the president and controlling shareholder of Supra. Dr. O'Brien holds a PhD from Carleton University where he conducted research at the Chemical Metrology group of the National Research Council. He was a professor in Analytical Chemistry for more than 13 years, developing numerous graduate and undergraduate courses in Advanced Analytical Instrumentation techniques and Forensic Chemistry. Dr. O'Brien is an expert in analytical instrumentation and has set up a number of advanced analytical laboratories. Dr. O'Brien was also the founder of Supra Research and Development, the first spin off company from the UBC Okanagan campus, created to commercialize innovative biomass extraction technology. Over his career, Dr. O'Brien has secured well over \$3 million dollars in research grants and has an extensive network of research collaborators. The Company granted incentive stock options to the newly appointed president of the Company's subsidiary to purchase up to 320,000 common shares of the Company at a price of \$1.25 per common share. The stock options are exercisable on or before February 29, 2020 and vest in stages over the course of three years. On March 2, 2017 20,000 of the options were exercised.

On March 14, 2017 the Company announced that Mr. Mark Doucet has joined the Company as its President. Mark Doucet has more than 25 years of senior executive experience. He has been involved in and advised on capital markets, infrastructure, commercial real estate, precious metals and other industries both foreign and domestic. Past service includes: President of a US junior exploration company, President of a business/government relations company, Founder and President of a wireless application company, and Vice President for several Canadian junior exploration companies, an international government/business consulting firm and an Atlantic Canada restaurant franchise. Mark served as Financial Officer and Development Planner for the privatization and redevelopment of Toronto's Pearson International Airport. Mark and his wife have two boys, and resides in Ottawa. The Company granted incentive stock options to the newly appointed president of the Company to purchase up to 1,000,000 common shares of the Company at a price of \$1.40 per common share. The stock options are exercisable on or before March 15, 2019 and vest in stages over the first two years.

RESULTS OF OPERATIONS

For the year ended November 30, 2016, the Company reported a loss of \$8,332,638 (\$0.16 per share), compared to \$591,796 (\$0.04 per share) for the comparable period in 2015. The increase in the loss reported is due to RTO transaction cost, specifically the listing expense, increase in management and professional fees, and increase in share-based payment charges.

SELECTED FINANCIAL INFORMATION

The following table sets out selected annual financial information for the last three financial years. The financial data has been prepared in accordance with IFRS.

| | 2016 | 2015 | 2014 |
|-------------------------------|-------------|-------------|-----------|
| | \$ | \$ | \$ |
| Operating expenses | (8,474,275) | (724,320) | (300,974) |
| Loss and comprehensive loss | (8,332,638) | (591,796) | (300,974) |
| Basic loss per common share | (0.16) | (0.04) | (0.04) |
| Diluted loss per common share | (0.16) | (0.04) | (0.04) |
| Working capital deficiency | (3,802,846) | (2,294,491) | (756,749) |
| Total assets | 2,747,234 | 1,548,864 | 496,326 |
| Total liabilities | 3,887,158 | 2,441,364 | 797,030 |

The Company is seeking to acquire one or more cash-flow capable projects. To date the Company has generated revenues of \$105,000 as at November 30, 2016 (\$132,524-2015 and \$Nil-2014).

At November 30, 2016, the Company had not yet achieved profitable operations and has accumulated losses of \$9,225,408 (2015-\$892,770; 2015: \$300,974) since inception. These losses resulted in a net basic loss per share for the year ended November 30, 2016 of \$0.16 (2015 - \$0.04; 2014 - \$0.02).

SUMMARY OF QUARTERLY REPORTS

Results for the most recent quarters ending with the last quarter for the year ended November 30, 2016, prepared using accounting principles consistent with IFRS:

| | Three Months Ended | | | |
|----------------------------------|----------------------|--------------------|-----------------|----------------------|
| | November 30, 2016 | August 31, 2016 | May 31, 2016 | February 28, 2016 |
| | \$ | \$ | \$ | \$ |
| Consulting income | - | - | 42,500 | 62,500 |
| Loss and comprehensive loss | (7,947,202) | (196,538) | (147,323) | (41,575) |
| Basic and diluted loss per share | (0.16) | (0.02) | (0.01) | (0.00) |

| | Three Months Ended | | | |
|----------------------------------|----------------------|--------------------|-----------------|----------------------|
| | November 30, 2015 | August 31, 2015 | May 31, 2015 | February 28, 2015 |
| | \$ | \$ | \$ | \$ |
| Consulting income | 131,524 | - | 1,000 | |
| Loss and comprehensive loss | (155,422) | (396,977) | (2,486) | (6,911) |
| Basic and diluted loss per share | (0.04) | (0.03) | (0.00) | (0.00) |

Quarterly results will vary in accordance with the Company's project acquisition and financing activities.

Variances quarter over quarter can be explained as follows:

Due to the Acquisition of VAL and RTO transaction, there was an increase in operating expenses from \$155,422 in the quarter ended November 30, 2015 to \$7,947,202 in the quarter ended November 30, 2016.

- Operating expenses increased primarily due to the following:
 - Increase in listing expense of \$7,243,265
 - Increased professional fees of \$86,586
 - Increased wages and salaries due to new hire of \$10,000
- In the quarter ended November 30, 2016, stock options were granted to various parties. Share-based payments were incurred of \$399,295 (November 30, 2015 - \$Nil).

Fourth Quarter

During the quarter ended November 30, 2016, operating expenses totaled \$7,947,202, primarily consisting of management fees of \$28,813, listing expense of \$7,144,548, rent of \$81,207, share-based payments of \$399,295 and professional fees of \$106,586.

GENERAL AND ADMINISTRATIVE

The operating expenses for the year ended November 30, 2016 totaled \$8,474,275 (November 30, 2015 - \$724,320), including share-based payments issued during the year, valued at \$399,295 (November 30, 2015 - \$Nil) calculated using the Black Scholes option pricing model. Comparatively, the major expenses for the year ended November 30, 2016 were management fees of \$179,313 (November 30, 2015 - \$159,000), listing expense of \$7,243,265 (November 30, 2015 - \$Nil), professional fees of \$259,909 (November 30, 2015 - \$108,857), rent of \$250,766 (November 30, 2015 - \$363,173), administration fees of \$14,000 (November 30, 2015 - \$35,700), telephone and utilities of \$32,985 (November 30, 2015 - \$41,811) and wages and salaries of \$53,879 (November 30, 2015 - \$Nil).

The table below details the changes in major expenditures for the year ended November 30, 2016 as compared to the corresponding year ended November 30, 2015:

| Expenses | Increase in Expenses | Explanation for Change |
|--------------------------|-----------------------------|---|
| Management fees | Increase of \$20,313 | Increase in management's compensation due to changes in management and RTO transaction. |
| Listing expense | Increase of \$7,243,265 | Increase due to the Acquisition of VAL and RTO transaction. |
| Professional fees | Increase of \$151,052 | Increase due to legal fees for the Acquisition of VAL and RTO transaction. |
| Rent | Decrease of \$112,407 | Decrease due to catch up rent to current compared with previous year which was included some of 2014 rent expenses. |
| Administration fees | Decrease of \$21,700 | Decrease due to less administration activates which resulted in lower cost. |
| Telephone and utilities | Decrease of \$8,826 | Decrease due primarily to decrease in initial set up costs. |
| Wages and salaries | Increase of \$53,879 | Increase due to new hire. |
| Share-based compensation | Increase of \$399,295 | Increase due to increase in granting of stock options to management and consultants. |

FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

As at November 30, 2016, the Company's liquidity and capital resources are as follows:

| | November 30, 2016 \$ | November 30, 2015 \$ |
|----------------------------------|----------------------------|----------------------------|
| Cash | 14,843 | 9,515 |
| Receivables | 68,583 | 137,358 |
| Prepaid expenses | 886 | - |
| Total current assets | 84,312 | 146,873 |
| Payables and accrued liabilities | 3,887,158 | 2,441,364 |
| Working capital deficit | (3,802,846) | (2,294,491) |

As at November 30, 2016, the Company had a cash position of \$14,843 (November 30, 2015 - \$9,515) derived from the net proceeds of private placements and cash acquired as a result of RTO. As at November 30, 2016, the Company had a working capital deficit of \$3,887,158 (November 30, 2015 - \$2,294,491).

The Company's continuation as a going concern is dependent upon successful results from its acquisition efforts and its ability to attain profitable operations and generate funds therefrom and/or raise equity capital or borrowings sufficient to meet current and future obligations. Management intends to finance operating costs over the next twelve months with current cash on hand, proceeds from the exercise of warrants and stock options, and further private placements. There is no assurance that the Company will be successful in raising additional capital on commercially reasonable terms or at all. See "Risks and Uncertainties".

OFF-BALANCE SHEET AGREEMENTS

The Company has not engaged in any off-balance sheet arrangements such as obligations under guarantee contracts, a retained or contingent interest in assets transferred to an unconsolidated entity, any obligation under derivative instruments or any obligation under a material variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to the Company or engages in leasing or hedging services with the Company.

COMMITMENTS

During the year ended November 30, 2015, the Company entered into a lease agreement with a company jointly owned by two directors of the Company. Under the agreement the Company is required to make monthly lease payments. The term of the lease is seven years with the option to renew for an additional three-year term. If the Company decides not to continue with the lease they will forfeit all leasehold improvements made up to the termination date. The lease payments under the agreement are as follows:

| Lease Year | Per Month | Per Annum |
|------------|-----------|-----------|
| 1 – 2 | \$16,500 | \$198,000 |
| 3 – 4 | \$16,995 | \$203,940 |
| 5 – 7 | \$17,505 | \$210,060 |

Based on the lease payments the remaining commitments are:

| | |
|---|----------------|
| Short term (December 1, 2016 - November 30, 2017) | \$ 203,445 |
| Long term (December 1, 2017- December 31, 2022) | <u>851,110</u> |
| | \$1,054,555 |

CONTINGENCY

During the year ended November 30, 2015, a small claims action was brought against the Company from a vendor the Company had used for services in the year. The outcome of the claim is uncertain. The Company has completed the requisite filings and is working to resolve the claim.

TRANSACTIONS WITH RELATED PARTIES

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include officers, directors or companies with common directors of the Company.

During the year ended November 30, 2016 the Company engaged in the following transactions with related parties, not disclosed elsewhere in this MD&A:

- (a) paid or accrued management fees of \$75,000 (2015 – \$75,000) to a director of the Company.
- (b) paid or accrued management fees of \$84,000 (2015 – \$84,000) to a company controlled by a director of the Company.
- (c) paid or accrued \$250,766 (2015 - \$253,810) in rent expense, to a director and a company controlled by a director of the Company.

Share-based payments include stock options granted to directors and officers recorded at a fair value of \$311,450 (2015 - \$nil).

As at November 30, 2016, accounts payable and accrued liabilities included \$3,659,368 (2015 - \$2,327,225) payable to directors, officers and companies controlled or related to directors and/or officers. Amounts payable to related parties have no specific terms of repayment, are unsecured and do not bear interest.

In accordance with IAS 24, key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including directors (executive and non-executive) of the Company.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of the financial statements in conformity with IFRS requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, as well as the reported revenues and expenses during the reporting period. Based on historical experience and current conditions, management

makes assumptions that are believed to be reasonable under the circumstances. These estimates and assumptions form the basis for judgments about the carrying value of assets and liabilities and reported amounts for revenues and expenses. Different assumptions would result in different estimates, and actual results may differ from results based on these estimates. These estimates and assumptions are also affected by management's application of accounting policies. Critical accounting estimates are those that affect the financial statements materially and involve a significant level of judgment by management.

Although management uses historical experience and its best knowledge of the amount, events or actions to form the basis for judgments and estimates, actual results may differ from these estimates.

Significant assumptions about the future and other sources of estimation uncertainty that management has made at the end of the reporting period, that could result in a material adjustment to the carrying amounts of assets and liabilities in the event that actual results differ from assumptions made, relate to, but are not limited to, the following:

- i) The inputs used in calculating the fair value for share-based compensation expense included in profit or loss.
- ii) The valuation of shares issued in non-cash transactions, including the settlement of debt and RTO transaction. Generally, the valuation of non-cash transactions is based on the value of the goods or services received. When non-cash transactions are entered into with employees and those providing similar services, the non-cash transactions are measured at the fair value of the consideration given up using market prices.
- iii) Collectability of promissory note receivable from MKHS, LLC.

NEW ACCOUNTING STANDARDS AND INTERPRETATION

Accounting standards not yet effective

IFRS 9, Financial Instruments – Classification and Measurement

IFRS 9 is a new standard on financial instruments that will replace IAS 39, Financial Instruments: Recognition and Measurement.

IFRS 9 addresses classification and measurement of financial assets and financial liabilities as well as de-recognition of financial instruments. IFRS 9 has two measurement categories for financial assets: amortized cost and fair value. All equity instruments are measured at fair value. A debt instrument is at amortized cost only if the entity is holding it to collect contractual cash flows and the cash flows represent principal and interest. Otherwise it is at fair value through profit or loss. IFRS 9 is effective for annual periods beginning on or after January 1, 2018.

IFRS 15, Revenue from Contracts with Customers

IFRS 15 specifies how and when an IFRS reporter will recognize revenue as well as requiring such entities to provide users of financial statements with more informative and relevant disclosures. The standard provides a single, principles based five-step model to be applied to all contracts with customers.

IFRS 15 was issued in May 2014 and applies to an annual reporting period beginning on or after January 1, 2018.

IFRS 11, Joint Arrangements

IFRS 11 is amended to provide specific guidance on accounting for acquisition of an interest in a joint operation that is a business. The amended standard is effective for annual periods beginning on or after January 1, 2016.

IAS 16, Property, plant and equipment and IAS 38 – Intangibles

IAS 16 and IAS 38 were issued in May 2014 and prohibit the use of revenue-based depreciation methods for property, plant and equipment and limit the use of revenue-based amortization for intangible assets. These amendments are effective for annual periods beginning on or after January 1, 2016 and are to be applied prospectively.

The Company has initially assessed that there will be no material reporting changes as a result of adopting the above new standards; however, enhanced disclosure requirements are expected.

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

1. Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities
2. Level 2 – inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
3. Level 3 – inputs that are not based on observable market data.

| | Financial assets at fair value | | | November 30, 2016 |
|--|--------------------------------|---------|---------|----------------------|
| | Level 1 | Level 2 | Level 3 | |
| Fair value through profit and loss financial asset | | | | |
| Cash | \$14,843 | - | - | \$ 14,843 |
| Total financial assets at fair value | \$14,843 | - | - | \$ 14,843 |

| | Financial assets at fair value | | | November 30, 2015 |
|--|--------------------------------|---------|---------|----------------------|
| | Level 1 | Level 2 | Level 3 | |
| Fair value through profit and loss financial asset | | | | |
| Cash | \$ 9,515 | - | - | \$ 9,515 |
| Total financial assets at fair value | \$ 9,515 | - | - | \$ 9,515 |

Cash is classified as fair value through profit or loss and is measured using level 1 inputs of the fair value hierarchy. The fair value of the Company’s receivables and accounts payable and accrued liabilities approximate their carrying values due to their short term nature. They are classified as loans and receivables.

Loans and long-term debt are measured at amortized cost. The fair value of the Company’s promissory note receivable is presented on an amortized costs basis and will be accreted to its face amount over the term to maturity of the loan at an effective interest rate.

The Company is exposed to varying degrees to a variety of financial instrument related risks. The Board approves and monitors the risk management processes, inclusive of counterparty limits, controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and promissory note receivable. The Company’s cash is held through large Canadian financial institutions and the Company’s promissory note receivable is guaranteed by MKHS.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to pay financial instrument liabilities as they come due. The Company currently does not have sufficient capital in order to meet short-term business requirements, after taking into account the Company’s holdings of cash. The Company is exposed to liquidity risk.

Market risk

The only market risk exposure to which the Company is exposed is interest rate risk. The Company's bank account earns interest income at variable rates. The fair value of its portfolio is relatively unaffected by changes in short-term interest rates. The Company's future interest income is exposed to short-term rates.

Foreign currency risk

The Company is nominally exposed to foreign currency risk on fluctuations related to cash and accounts payable and accrued liabilities that are denominated US Dollars (USD or US\$).

Price risk

The Company is exposed to price risk with respect to commodity and equity prices. Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices or general movements in the level of the stock market. Commodity price risk is defined as the potential adverse impact on earnings and economic value due to commodity price movements and volatilities. The Company closely monitors commodity prices of raw materials, individual equity movements, and the stock market to determine the appropriate course of action to be taken by the Company.

CAPITAL MANAGEMENT

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to maintain operations. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital that it manages as shareholders' deficiency.

The Company has historically relied on the equity markets to fund its activities. Current financial markets are very difficult and there is no certainty with respect to the Company's ability to raise capital. Management reviews its capital management approach on an on-going basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company currently is not subject to externally imposed capital requirements. There were no changes to the Company's approach to capital management.

RISKS AND UNCERTAINTIES

Many factors could cause our actual results, performance and achievements to differ materially from those expressed or implied by the forward-looking statements and forward-looking information, including without limitation, the following factors, which are discussed in greater detail under the heading "Risk Factors" in our draft Listing Statement dated May 5, 2016 filed with the CSE and available on www.thecse.com, which risk factors are incorporated by reference into this document, and should be reviewed in detail by all readers:

- Our ability to grow, store and sell medical marijuana in Canada is dependent upon licenses from Health Canada which are subject to ongoing compliance and reporting requirements;
- The activities of the Company are subject to regulation by governmental authorities, particularly Health Canada;
- The Company's operations are subject to various laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of medical marijuana but also including laws and regulations relating to health and safety, the conduct of operations and the protection of the environment;
- Third parties the Company does business with may perceive that they are exposed to reputational risk as a result of the Company's medical marijuana business activities;
- The operation of the Company can be impacted by adverse changes or developments affecting the facilities of the Company's wholly-owned subsidiaries;
- The Company's ability to recruit and retain management, skilled labour and suppliers is crucial to the Company's success;
- The Company's growth strategy contemplates outfitting its facilities with additional production resources. A variety of factors could cause these activities to not be achieved on time, on budget, or at all. As a result, there is a risk that the

Company may not have product or sufficient product available to meet the anticipated demand or to meet future demand when it arises;

- The Company and its wholly-owned subsidiaries have limited operating histories;
- The Company has a history of net losses, may incur significant net losses in the future and may not achieve or maintain profitability;
- Even if its financial resources are sufficient to fund its current operations, there is no guarantee that the Company will be able to achieve its business objectives. The continued development of the Company may require additional financing and there can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favourable to the Company;
- There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and manufacturing and marketing experience than the Company;
- The Company believes the marijuana industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the marijuana produced. Consumer perception of the Company's products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of marijuana products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the medical marijuana market or any particular product, or consistent with earlier publicity;
- The Company and its wholly-owned subsidiaries face an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury;
- The products of the Company's wholly-owned subsidiaries could be subject to the recall or return of their products for a variety of reasons. If a product recall or return should happen, the Company could be required to incur unexpected expenses and divert management attention and could see harm caused to its image and product sales decline. In addition, as result of the product recall or return, the Company and its wholly-owned subsidiaries could face increased operational scrutiny by Health Canada or other regulatory agencies, requiring further management attention and potential legal fees and other expenses;
- Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company;
- The Company is largely reliant on its own market research to forecast sales as detailed forecasts are not generally obtainable from other sources at this early stage of the medical marijuana industry in Canada. A failure in the demand for its products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company;
- The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls;
- The Company may engage in acquisitions or other strategic transactions or make investments that could result in significant changes or management disruption;
- The Company could fail to integrate acquired companies into the business of the Company;
- Completed acquisitions, strategic transaction or investments could fail to increase shareholder value;
- The Company may become party to litigation, mediation and/or arbitration from time to time in the ordinary course of business which could adversely affect its business;
- There can be no assurance that an active and liquid market for the common shares will be maintained and an investor may find it difficult to resell any securities of the Company;

- A substantial number of common shares are owned by a limited number of existing shareholders and as such these shareholders are in a position to exercise influence over matters requiring shareholder approval or cause delay or prevent a change in control of the Company that could otherwise be beneficial to the Company's shareholders;
- The Company does not anticipate paying any dividends on the common shares in the foreseeable future. Dividends paid by the Company would be subject to tax and, potentially, withholdings;
- The Company's operations are subject to environmental and safety laws and regulations concerning, among other things, emissions and discharges to water, air and land; the handling and disposal of hazardous and non-hazardous materials and wastes, and employee health and safety; and
- In recent years, securities markets have experienced extremes in price and volume volatility. The market price of securities of many early stage companies, among others, have experienced fluctuations in price which may not necessarily be related to the operating performance, underlying asset values or prospects of such companies. It may be anticipated that any market for the Company's shares will be subject to market trends generally and the value of the Company's shares on a stock exchange may be affected by such volatility.
- Unfavorable economic conditions may negatively impact the Company's financial viability as a result of increased financing costs and limited access to capital markets.
- The Company is very dependent upon the personal efforts and commitment of its existing management. To the extent that management's services would be unavailable for any reason, a disruption to the operations of the Company could result, and other persons would be required to manage and operate the Company.
- The Company's directors and officers may serve as directors and officers, or may be associated with other reporting companies or have significant shareholdings in other public companies. To the extent that such other companies may participate in business or asset acquisitions, dispositions, or ventures in which the Company may participate, the directors and officers of the Company may have a conflict of interest in negotiating and concluding terms respecting the transaction. If a conflict of interest arises, the Company will follow the provisions of the Business Corporations Act, British Columbia ("Corporations Act") in dealing with conflicts of interest. These provisions state, where a director/officer has such a conflict, that the director/officer must at a meeting of the board, disclose his interest and refrain from voting on the matter unless otherwise permitted by the Corporations Act. In accordance with the laws of the Province of British Columbia, the directors and officers of the Company are required to act honestly, in good faith and in the best interests of the Company.

ADDITIONAL DISCLOSURE FOR VENTURE ISSUERS WITHOUT SIGNIFICANT REVENUE

Dividends

The Company has no earnings or dividend record and is unlikely to pay any dividends in the foreseeable future as it intends to employ available funds for oil and gas exploration and development. Any future determination to pay dividends will be at the discretion of the board of directors and will depend on the Company's financial condition, results of operations, capital requirements and such other factors as the board of directors deem relevant.

Management's Responsibility for Financial Statements

The information provided in this report, including the financial statements, is the responsibility of management. In the preparation of these statements, estimates are sometimes necessary to make a determination of future values for certain assets or liabilities. Management believes such estimates have been based on careful judgments and have been properly reflected in the accompanying financial statements.

In contrast to the certificate required under National Instrument 52-109 Certificate of Disclosure in Issuers' Annual and Interim Filings ("NI 52-109"), the Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures ("DC&P") and internal control over financial reporting ("ICFR"), as defined in NI 52-109, in particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:

(i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the Company in its annual filings, interim filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

(ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the Company's GAAP.

The issuer's certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate. Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of interim and annual filings and other reports provided under securities legislation.

Nature of the Securities

The purchase of the Company's securities involves a high degree of risk and should be undertaken only by investors whose financial resources are sufficient to enable them to assume such risks. The Company's securities should not be purchased by persons who cannot afford the possibility of the loss of their entire investment. Furthermore, an investment in the Company's securities should not constitute a major portion of an investor's portfolio.

Proposed Transactions

There are currently no significant proposed transactions except as otherwise disclosed in this MD&A. Confidentiality agreements and non-binding agreements may be entered into from time to time, with independent entities to allow for discussions of the potential acquisition and/or development of certain properties.

Approval

The Board of Directors oversees management's responsibility for financial reporting and internal control systems through an Audit Committee. This Committee meets periodically with management and annually with the independent auditors to review the scope and results of the annual audit and to review the financial statements and related financial reporting and internal control matters before the financial statements are approved by the Board of Directors and submitted to the shareholders of the Company. The Board of Directors of the Company has approved the financial statements and the disclosure contained in this MD&A. A copy of this MD&A will be provided to anyone who requests it.

Additional Information

Additional information related to the Company is available for view on SEDAR at www.sedar.com.

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCING REPORTING

In connection with National Instrument ("NI") 52-109 (Certification of Disclosure in Issuer's Annual and Interim Filings) adopted in December 2008 by each of the securities commissions across Canada, the Chief Executive Officer and Chief Financial Officer of the Company will file a Venture Issuer Basic Certificate with respect to the financial information contained in the unaudited interim financial statements and the audited annual financial statements and respective accompanying Management's Discussion and Analysis. The Venture Issuer Basic Certification does not include representations relating to the establishment and maintenance of disclosure controls and procedures and internal control over financial reporting, as defined in NI 52-109.

OUTSTANDING SHARES, OPTION, AND WARRANTS

The Company has one class of common shares. Below is a summary of the common shares issued and outstanding as at November 30, 2016 and the date of this report:

| | As at November 30, 2016 | As at March 29, 2017 |
|---------------|--------------------------------|-----------------------------|
| Common shares | 51,022,667 | 53,195,857 |
| Stock options | 2,905,000 | 4,205,000 |
| Warrants | 944,444 | 2,021,039 |

Stock options

The Company has issued incentive options to certain directors, employees, officers, and consultants of the Company. As of the date of this report the following options outstanding:

| Options outstanding | Options exercisable | Exercise price \$ | Expiry date |
|----------------------------|----------------------------|--------------------------|----------------------|
| 36,667 | 36,667 | 3.00 | September 25, 2017 |
| 40,000 | 40,000 | 3.00 | October 10, 2018 |
| 20,000 | 20,000 | 3.00 | November 27/28, 2018 |
| 258,333 | 258,333 | 0.30 | August 31, 2020 |
| 50,000 | 50,000 | 0.30 | September 22, 2020 |
| 2,500,000 | 1,250,000 | 0.65 | November 30, 2021 |
| 300,000 | 80,000 | 1.25 | February 29, 2020 |
| 1,000,000 | 250,000 | 1.40 | March 15, 2019 |

Warrants

The Company has issued warrants as part of its non-brokered private placements. As of the date of this report the Company has 944,444 warrants outstanding.

| Warrants issue date | Number of warrants outstanding | Exercise price \$ | Expiry date |
|----------------------------|---------------------------------------|--------------------------|--------------------|
| September 22, 2015 | 622,222 | 0.75 | September 22, 2017 |
| October 23, 2015 | 322,222 | 0.75 | October 23, 2017 |
| December 20, 2016 | 497,288 | 1.15 | December 21, 2017 |
| January 10, 2017 | 579,307 | 1.15 | January 11, 2018 |

DIRECTORS AND OFFICERS

Robert van Santen – *Chairman, Chief Executive Officer, Director*

Annie Storey - *Chief Financial Officer, Corporate Secretary*

David Gervais – *Director*

Tim Tombe - *Director*

A. Tyler Robson - *Director*

John Binder - *Director*

OTHER REQUIREMENTS

Additional disclosure of the Company’s technical reports, material change reports, news releases and other information can be obtained on SEDAR at www.sedar.com.

On Behalf of the Board,

VALENS GROWWORKS CORP.

“Robert van Santen”

Robert van Santen

“Tim Tombe”

Tim Tombe